ArticleJournal of immunology (Baltimore, Md. : 1950)2026
T-cell miR-155 regulates the response to tumor-specific mRNA vaccines in a murine model of acute myeloid leukemia.
Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Acute myeloid leukemia (AML) is a malignant clonal expansion of myeloid progenitor cells that impedes normal hematopoiesis and culminates in bone marrow failure and death. The development of chemoresistant disease in response to first-line chemotherapies is common and indicates a need for new therapies. Tumor-specific mRNA vaccines have emerged as potent inducers of cellular immunity against solid tumors, yet their utility in targeting AML and the specific mechanisms that govern their broader activity remain poorly defined. Here, we demonstrate that microRNA-155 (miR-155) within T cells is vital for host anti-leukemia responses at baseline, and for mRNA vaccine-elicited cellular responses against AML. Loss of miR-155 in T cells in conditional knockout (TCKO) mice (miR-155 fl/fl CD4+Cre) results in deficient antitumor immunity against syngeneic ovalbumin-expressing C1498 murine AML (C1498-OVA). T cell-intrinsic miR-155 is required for terminal differentiation of short-lived effector KLRG1+ CD8+ T cells, thereby providing protective immunity induced by a tumor Ag-specific mRNA vaccine against C1498-OVA AML. Single-cell RNA sequencing reveals distinct miR-155-dependent transcriptomic regulation during the mRNA vaccine response. including changes indicative of a failure to appropriately respond to IFN-γ signaling in miR-155 TCKO CD8+ T cells. Notably, we identify a subset of genes modulated by miR-155 in CD8+ T cells specific to response to mRNA vaccination, indicating a novel and context-specific role for miR-155 in regulating the immune response to mRNA-lipid nanoparticle therapeutics. Together, these data indicate T cell-expressed miR-155 is a master regulator of intrinsic cellular immunity to AML and promotes tumor-specific mRNA vaccine responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.